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T  cell  tolerance  depends on  the  presentation of self- 
proteins to T cells and therefore can only be established 
to those self-determinants which, under steady-state condi- 
tions, are generated in sufficient amounts to be recognized 
by T cells undergoing deletion in thymus or anergy in the 
periphery.  Thus, there is large number of self-determinants 
that are cryptic because they are not generated at all or are 
generated at subthreshold levels. T cells specific  for these cryptic 
epitopes are present in the normal repertoire and might be- 
come activated and autoaggressive if the epitopes are presented 
at higher concentrations. This concept, which had been orig- 
inally proposed by Sercarz and colleagues, represents  today 
the major hypothesis for the pathogenesis of autoimmune 
diseases (1). The fundamental question is how epitopes that 
are normally cryptic may become visible to the immune system 
and elicit  a sustained  pathogenetic response. 
Two reports in this issue of The Journal of Experimental 
Medicine describe two novel mechanisms that may be respon- 
sible for revealing cryptic determinants. It is tempting to put 
this new information together with previous reports to try 
to delineate how different mechanisms may synergize for the 
induction, development, and maintenance of an autoimmune 
response. 
Processing Boosted by Receptor Down-regulation 
It is well established that endogenous cellular proteins are 
presented on class II molecules at levels that depend on their 
capacity to enter the processing compartment (2). Barnaba 
and co-workers demonstrate that down-regulation of a cell 
surface protein induced by an external ligand may result in 
increased processing and presentation of otherwise cryptic 
epitopes (3). These authors have isolated from HIV-infected 
patients DR-restricted T cell clones specific for human CD4 
determinants, which have been mapped to two distinct sites 
using synthetic peptides. These clones recognize EBV-B cells 
that take up and present engineered soluble CD4 molecules, 
but do not recognize T cell clones that are growing in IL-2, 
although the latter express both CD4 and class II molecules. 
Thus, the epitopes defined by these clones are cryptic since 
they are not generated (or at least not at sufficient levels) by 
constitutive processing of the endogenous CD4. Strikingly 
however, these epitopes are readily generated by activated T 
cells when surface CD4 is down-regulated by HIV-gp120 or 
by antibodies to CD4. 
How is it that some autoreactive CD4-specific T cells can 
escape tolerance induction in the thymus and be activated 
in the periphery? The most plausible explanation is that the 
epitopes recognized by these T  cells may not be generated 
in the thymus, where CD4 peptides are presented by phago- 
cytic cells that process endogenous CD4 molecules or phagocy- 
tose dying thymocytes. The reported evidence that these epi- 
topes  are  produced only by  activated  T  cells after  CD4 
down-regulation suggests that both quantitative and qualita- 
tive changes in processing may be involved. A larger number 
of molecules will be targeted to degradation and these mole- 
cules may be delivered to a different endocytic compartment 
containing different sets of proteases, such as granzymes. It 
is also possible that ligand binding may influence processing 
as discussed below. As a consequence of their differential ex- 
pression,  these epitopes will  not  induce tolerance in  the 
thymus, but it will induce a specific response in periphery 
when presented by activated T cells. Indeed, activated T cells 
are able to present antigen (4) and to prime naive T cells (5, 6). 
The findings reported by Salemi et al. (3) have important 
implications for HIV pathogenesis because they establish an 
important link between the immune response to the virus 
and autoimmunity. In HIV-infected patients, CD4 can be 
efficiently down-regulated by gp120, especially if crosslinked 
by anti-gp120 antibodies.  Presentation of cryptic CD4 epi- 
topes on activated T cells, which function as professional APC, 
may result in priming of CD4-specific T cells. These, in turn, 
could then attack activated T cells in which CD4 has been 
downregulated by gp120 (or perhaps by antigenic stimula- 
tion as discussed below). Alternatively,  CD4-specific T cells 
could help B cells to make anti CD4 antibodies,  which will 
further boost the response by increasing CD4 down-regula- 
tion. This HIV immunopathology  could be also initiated by 
the production of anti-CD4 antibodies induced by CD4-gp120 
complexes and gp120-specific T cells by the classical mecha- 
nism of intermolecular help (7). 
In addition to the potentially important role in HIV patho- 
genesis, the model proposed by Barnaba and colleagues may 
represent a general mechanism for presentation of TCR epi- 
topes to T  cells. Indeed, antigen stimulation is known to 
lead to massive down-regulation of TCR and coreceptors. 
Thus, one can expect that cryptic epitopes may be transiently 
presented by T and B cells after antigenic stimulation. Pre- 
sentation will be facilitated by two simultaneous events that 
follow T cell activation:  the increase in class II synthesis and 
the up-regulation of adhesion and costimulatory molecules (6). 
It is tempting to suggest that class II-restricted presenta- 
tion of cryptic epitopes of the TCR and possibly also of the 
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of regulatory T  cell responses, may be more frequent than 
expected. The use of recently activated T or B cells as targets 
or stimulators may be the key to reveal these responses in vitro. 
Processing Altered by Ligand Binding 
It is well known that antibodies can increase the efficiency 
of antigen capture in antigen-specific B cells and in FcR + 
professional APC, a mechanism that has been implicated in 
the generation of cryptic epitopes and in the consequent au- 
toimmune responses (8). More than a decade ago, Berzofsky, 
Celada, and co-workers suggested that antibodies may also 
affect antigen processing (9, 10). Watts and co-workers now 
demonstrate that antibodies can modulate processing of anti- 
gen so that the production of some epitopes can be increased 
10-100-fold (11). 
This study is the culmination of a series of experiments 
carried out in this laboratory during the last several years. 
The starting observation was that high affinity antibody does 
not dissociate from antigen at the mildly acidic pH of the 
processing compartment and, therefore, the substrate for pro- 
teases is the antigen antibody complex rather than antigen 
alone. The influence of antibody binding on processing has 
been studied biochemically by monitoring the appearance of 
distinct proteolytic antigenic fragments still bound to Ig (12) 
and functionally by analyzing the capacity of APCs to trigger 
T  cell clones specific for different determinants (13). 
Simitsek et al. (11) have used a system that makes it pos- 
sible to discriminate between the effect of antibody on an- 
tigen uptake and the effect on antigen processing. They show 
that antibody binding can suppress  the generation of some 
epitopes, while at the same time boosting the generation of 
others. Remarkably, both boosted and suppressed epitopes 
are present within a protein domain that is "footprinted" by 
the antibody, while epitopes that lie outside this domain are 
not affected. The mechanisms responsible for these contrasting 
effects are not clear, but certainly do not involve competition 
for MHC binding. It is possible that the antibody, by binding 
and stabilizing a protein domain, may influence the accessi- 
bility of the site to proteases.  Trimming of an antigen frag- 
ment bound to Ig may result in the destruction of some epi- 
topes and simultaneous increased yield of others. An alternative 
possibility is that antibody may facilitate transfer of some de- 
terminants to class II molecules, which are known to be able 
to bind large unfolded fragments. 
In this study, the epitope that is boosted by antibody is 
not cryptic in a strict sense,  since it can be generated at a 
lower but stimulatory levels also in the absence of the anti- 
body. It is interesting to consider the possibility that the in- 
duction of a T cell response to this partially cryptic epitope 
might have followed the activation of B cells producing the 
boosting antibody, which can be induced by any antigen- 
specific T cell. This may result in a T-B circuit in which T 
cells  preferentially interact  with  B  cells  of the boosting 
specificity.  Thus,  this  mechanism has  dominant  and  self- 
sustaining properties since the boosting effect of antibody 
on antigen processing is likely to take place, not only in B 
cells, but also in professional APC that have taken up anti- 
gen- antibody complexes (13). In this way, the effect of anti- 
body on processing can be amplified and can exert a profound 
effect on the selection and diversification of the T cell responses. 
Although these results have been obtained using a bacterial 
antigen, the model is likely to be of general relevance for pre- 
sentation of self-antigens as well. Indeed, positive and nega- 
tive modulation of processing appear to be the inevitable con- 
sequence of high affinity binding and will influence processing 
of soluble as well as cellular proteins that are bound by high 
affinity ligands, not necessarily antibodies. 
Presentation of Cryptic Epitopes and Induction of 
Autoimmune Responses 
There are two distinct aspects that are relevant to under- 
stand the role of cryptic epitopes in autoimmune diseases: 
(a) the presentation of cryptic epitopes and (b) the triggering 
of a T  cell response. 
As shown in Fig. 1, the mechanisms responsible for gener- 
ation of cryptic epitopes fall into three general categories. 
The first is increased antigen delivery to the processing com- 
partment. This is the case when surface receptors are down- 
regulated by antibodies or other ligands (3). In addition, an 
important role may be played by membrane Ig on B cells 
or by soluble IgG antibodies that drive antigen capture by 
FcR + APC. The second general category is modulation of 
antigen processing, which may occur when antigen is bound 
to antibodies or high affinity ligands (11). Cryptic epitopes 
might also be generated by subtle changes in the processing 
machinery. It will be interesting to see whether different en- 
dosomal compartments may have a qualitatively different ca- 
pacity to process antigen. APCs may also express slightly 
different sets of proteases (14), and proteases can be regulated 
by exogenous stimuli such as cytokines (15, 16). The third 
category is an increase in class II synthesis or in expression 
of adhesion and costimulatory molecules. These mechanisms 
may enhance the yield of cryptic epitopes and may increase 
the T  cell stimulatory capacity. 
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Figure  1.  Mechanisms  that may lead  to presentation  of  cryptic  epitopes. 
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Figure  2.  Mechanisms  that may initiate and maintain an autoimmune 
response to cryptic epitopes (CE). 
It is important to point out that all these mechanisms may 
act  synergistically.  Antibodies  can  increase uptake,  induce 
down-regulation,  and modify processing. T or B cell activa- 
tion may induce receptor down-regulation and increased syn- 
thesis of class II and costimulatory molecules. Cytokines can 
increase synthesis of class II molecules and proteases. Thus, 
this process is catalytic in the sense that, after an initial trigger, 
the response may become self-sustaining through the reciprocal 
stimulatory  effect  of T  cells  and  B  cells,  antibodies  and 
cytokines, a fact that  may explain the spreading  of the au- 
toimmune  response (17). 
If these are plausible mechanisms, what could be the initi- 
ating  event  that  triggers  this "autoimmune  spiral"? 
A first attractive possibility is that the induction of an au- 
toimmune response follows the same rules as the induction 
of a response to foreign antigens,  namely presentation on den- 
dritic cells (Fig.  2). The function of these cells is to capture 
antigen at peripheral sites and migrate to T cell areas of lym- 
phoid organs, where they trigger naive T cells (18). Growing 
evidence indicates that dendritic cells have specialized mech- 
anisms for antigen capture,  and that  the antigen  capturing 
and migratory properties can be modulated by cytokines and 
inflammatory stimuli (19).  It will be important  to identify 
the conditions and the mechanisms that may allow dendritic 
cells  to take up and present  self antigens from dying cells. 
The  second  possibility  is  that  the  cryptic  epitopes  are 
presented on nonprofessional APC,  such as resting  B cells 
or epithelial cells. According to the current dogma,  T  cells 
should be anergized  rather  than  triggered  (20).  Neverthe- 
less, there may be cases where T  cells can be activated even 
if the antigen is presented on nonprofessional APC. This may 
occur at inflammatory  sites or in the microenvironment  of 
a lymph node where costimulation could be provided in a 
bystander fashion. Alternatively, T cells could be primed by 
recognition of a cross-reactive antigen presented by profes- 
sional  APC  as  a  result  of molecular  mimicry  (21)  or  of 
the presence of a second TCR with a different antigenic spec- 
ificity (22). 
The third possibility is that the initiating event is the acti- 
vation of autoreactive B cells.  This may well occur in the 
absence of T  cells specific for the self antigen.  For instance, 
autoreactive B cells could take up a self-antigen complexed 
with a foreign antigen and be stimulated by T  cells specific 
for the latter (23). Alternatively, autoreactive B cells may take 
up a foreign antigen that cross-reacts with a self-antigen at 
the B cell level,  but contains  different T  cell epitopes (8). 
Finally,  B cells can be directly activated by highly organized 
self antigen  (24).  While in most of these cases the autoAb 
responses are expected to be self-limited,  there is the possi- 
bility that  autoreactive T  cells may be primed by activated 
B cells that  efficiently take up and present self-antigen (8), 
or by dendritic cells that  take up self-antigen complexed to 
IgG antibodies. 
In conclusion, independently from the mechanism that has 
initiated the autoimmune spiral, the unveiling of cryptic epi- 
topes via the effect of antibody and cytokines on antigen cap- 
ture or processing may result in a self-sustained immune re- 
sponse that  is responsible for the  autoimmune  disease. 
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